Multi-omics reveals deoxycholic acid modulates bile acid metabolism via the gut microbiota to antagonize carbon tetrachloride-induced chronic liver injury

References

• Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol. 2014;20(10):2515–22. doi:10.3748/wjg.v20.i10.2515.
   PubMed Web of Science ®Google Scholar
• Cheng D, Chai J, Wang H, Fu L, Peng S, Ni X. Hepatic macrophages: key players in the development and progression of liver fibrosis. Liver Int. 2021;41(10):2279–2294. doi:10.1111/liv.14940.
   PubMed Web of Science ®Google Scholar
• Xiang J, Zhang Z, Xie H, Zhang C, Bai Y, Cao H, Che Q, Guo J, Su Z. Effect of different bile acids on the intestine through enterohepatic circulation based on FXR. Gut Microbes. 2021;13(1):1949095. doi:10.1080/19490976.2021.1949095.
   PubMed Web of Science ®Google Scholar
• Jia W, Wei M, Rajani C, Zheng X. Targeting the alternative bile acid synthetic pathway for metabolic diseases. Protein Cell. 2020;12(5):411–425. doi:10.1007/s13238-020-00804-9.
   PubMed Web of Science ®Google Scholar
• Cai J, Rimal B, Jiang C, Chiang JYL, Patterson AD. Bile acid metabolism and signaling, the microbiota, and metabolic disease. Pharmacology & Therapeutics. 2022;237:108238. doi:10.1016/j.pharmthera.2022.108238.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yue C, Zhang H, Chen H, Liu Y, Li J. Deoxycholic acid and lithocholic acid alleviate liver injury and inflammation in mice with Klebsiella pneumoniae-induced liver abscess and bacteremia. J Inflamm Res. 2021;14:777–89. doi:10.2147/JIR.S298495.
   PubMed Web of Science ®Google Scholar
• Xin C, Liu S, Qu H, Wang Z. The novel nanocomplexes containing deoxycholic acid-grafted chitosan and oleanolic acid displays the hepatoprotective effect against CCl(4)-induced liver injury in vivo. Int J Biol Macromol. 2021;185:338–349. doi:10.1016/j.ijbiomac.2021.06.109.
   PubMed Web of Science ®Google Scholar
• Sang C, Wang X, Zhou K, Sun T, Bian H, Gao X, Wang Y, Zhang H, Jia W, Liu P. et al. Bile acid profiles are distinct among patients with different etiologies of chronic liver disease. J Proteome Res. 2021;20(5):2340–51. doi:10.1021/acs.jproteome.0c00852.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs LP, Ma L, Roy S, Fu Q, Brown ZJ. et al. Gut microbiome directs hepatocytes to recruit MDSCs and promote Cholangiocarcinoma. Cancer Discov. 2021;11(5):1248–67. doi:10.1158/2159-8290.CD-20-0304.
   PubMed Web of Science ®Google Scholar
• Zhou R, Fan X, Schnabl B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res. 2019;209:22–38. doi:10.1016/j.trsl.2019.02.005.
   PubMed Web of Science ®Google Scholar
• Nicoletti A, Ponziani FR, Biolato M, Valenza V, Marrone G, Sganga G, Gasbarrini A, Miele L, Grieco A. Intestinal permeability in the pathogenesis of liver damage: from non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol. 2019;25(33):4814–4834. doi:10.3748/wjg.v25.i33.4814.
   PubMed Web of Science ®Google Scholar
• Wahlstrom A, Sayin SI, Marschall HU, Backhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50. doi:10.1016/j.cmet.2016.05.005.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, Brown RS, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi:10.1002/hep.29800.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2017;67(1):328–357. doi:10.1002/hep.29367.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases. Hepatology. 2018;69(1):394–419. doi:10.1002/hep.30145.
   PubMed Web of Science ®Google Scholar
• Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol‐related liver diseases: 2019 practice guidance from the American association for the study of liver diseases. Hepatology. 2020;71(1):306–333. doi:10.1002/hep.30866.
   PubMed Web of Science ®Google Scholar
• Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D. et al. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nat Commun. 2018;9(1):1614. doi:10.1038/s41467-018-03537-w.
   PubMedGoogle Scholar
• Aoyama T, Inokuchi S, Brenner DA, Seki E. CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice. Hepatology. 2010;52(4):1390–400. doi:10.1002/hep.23795.
   PubMed Web of Science ®Google Scholar
• Allen F, Pon A, Wilson M, Greiner R, Wishart D. CFM-ID: a web server for annotation, spectrum prediction and metabolite identification from tandem mass spectra. Nucleic Acids Res. 2014;42(W1):W94–9. doi:10.1093/nar/gku436.
   PubMed Web of Science ®Google Scholar
• Shen X, Wang R, Xiong X, Yin Y, Cai Y, Ma Z, Liu N, Zhu Z-J. Metabolic reaction network-based recursive metabolite annotation for untargeted metabolomics. Nat Commun. 2019;10(1):1516. doi:10.1038/s41467-019-09550-x.
   PubMedGoogle Scholar
• Ansaldo E, Slayden LC, Ching KL, Koch MA, Wolf NK, Plichta DR, Brown EM, Graham DB, Xavier RJ, Moon JJ. et al. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis. Science. 2019;364(6446):1179–84. doi:10.1126/science.aaw7479.
   PubMed Web of Science ®Google Scholar
• Wu W, Lv L, Shi D, Ye J, Fang D, Guo F, Li Y, He X, Li L. Protective effect of akkermansia muciniphila against immune-mediated liver injury in a mouse model. Front Microbiol. 2017;8:1804. doi:10.3389/fmicb.2017.01804.
   PubMed Web of Science ®Google Scholar
• Hagi T, Geerlings SY, Nijsse B, Belzer C. The effect of bile acids on the growth and global gene expression profiles in Akkermansia muciniphila. Appl Microbiol Biotechnol. 2020;104(24):10641–53. doi:10.1007/s00253-020-10976-3.
   PubMed Web of Science ®Google Scholar
• Wu W, Kaicen W, Bian X, Yang L, Ding S, Li Y, Li S, Zhuge A, Li L. Akkermansia muciniphila alleviates high-fat-diet-related metabolic-associated fatty liver disease by modulating gut microbiota and bile acids. Microb Biotechnol. 2023;16(10):1924–1939. doi:10.1111/1751-7915.14293.
   PubMedGoogle Scholar
• Du J, Zhang P, Luo J, Shen L, Zhang S, Gu H, He J, Wang L, Zhao X, Gan M. et al. Dietary betaine prevents obesity through gut microbiota-drived microRNA-378a family. Gut Microbes. 2021;13(1):1–19. doi:10.1080/19490976.2020.1862612.
   PubMed Web of Science ®Google Scholar
• Rao Y, Kuang Z, Li C, Guo S, Xu Y, Zhao D, Hu Y, Song B, Jiang Z, Ge Z. et al. Gut akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes. 2021;13(1):1–19. doi:10.1080/19490976.2021.1927633.
   PubMed Web of Science ®Google Scholar
• Guo C, Xie S, Chi Z, Zhang J, Liu Y, Zhang L, Zheng M, Zhang X, Xia D, Ke Y. et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity. 2016;45(4):802–16. doi:10.1016/j.immuni.2016.09.008.
   PubMed Web of Science ®Google Scholar
• Wree A, McGeough MD, Inzaugarat ME, Eguchi A, Schuster S, Johnson CD, Peña CA, Geisler LJ, Papouchado BG, Hoffman HM. et al. NLRP3 inflammasome driven liver injury and fibrosis: roles of IL-17 and TNF in mice. Hepatology. 2018;67(2):736–49. doi:10.1002/hep.29523.
   PubMed Web of Science ®Google Scholar
• Liu R, Li X, Huang Z, Zhao D, Ganesh BS, Lai G, Pandak WM, Hylemon PB, Bajaj JS, Sanyal AJ. et al. C/EBP homologous protein–induced loss of intestinal epithelial stemness contributes to bile duct ligation–induced cholestatic liver injury in mice. Hepatology. 2018;67(4):1441–1457. doi:10.1002/hep.29540.
   PubMed Web of Science ®Google Scholar
• Xue X, Wu J, Ding M, Gao F, Zhou F, Xu B, Lu M, Li J, Li X. Si-Wu-Tang ameliorates fibrotic liver injury via modulating intestinal microbiota and bile acid homeostasis. Chin Med. 2021;16(1):112. doi:10.1186/s13020-021-00524-0.
   PubMed Web of Science ®Google Scholar